The Current Landscape of Biosimilars in IBD

(16:44)

Biosimilars in #retina

(1:30)

The Complexity of Choosing Biosimilars in Oncology

(5:56)

Biosimilars Drugs in Canada

(2:6)

Pinpointing the Top Questions and Considerations about Biosimilars in Rheumatology

(34:22)

Dr. Verma Discusses Challenges With Biosimilars in Oncology

(1:42)

Biosimilars in the US and Beyond

(11:3)

Biosimilars in ten minutes: What you need to know | Tiago Torres, MD, PhD | Portugal

(10:5)

The Impact of Biosimilars in Canada: A Physician's Perspective with Dr. Brian Feagan

(12:29)

Dr. Welslau on the Benefits of Biosimilars in DLBCL

(1:15)

Are We Ready for Biosimilars in Multiple Sclerosis? Experts Discuss Lessons From Other Immune-Med...

(34:40)

To Switch or Not: Biosimilars in Inflammatory Arthritis

(2:57)

Biologics and Biosimilars in Multiple Sclerosis

(12:37)

Pinpointing the Top Questions and Considerations about Biosimilars in Dermatology

(30:20)

The Role of Biosimilars in the US Healthcare System

(7:34)

Dr. Brufsky Discusses Reasons to Use Biosimilars in Oncology

(54)

Pinpointing the Top Questions and Considerations about Biosimilars in Hematology/Oncology

(49:9)

Dr. Markman on the Concept of Biosimilars in Oncology

(1:48)

The Impact of Biosimilars in Canada: A Private Payer’s Perspective With Karen Voin

(9:55)

Biosimilars in IBD: Where Do We Stand Today?

(16:48)